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not support that hypothesis that PDB is associated with a 
persistent infection with measles or other paramyxoviruses.
Keywords Paget’s disease of bone · Paramyxovirus · 
Measles · Distemper · Genetic
Introduction
Paget’s disease of bone is a common skeletal disorder 
characterised by focal abnormalities of increased and dis-
organised bone turnover at one or more skeletal sites [1]. 
Many patients are asymptomatic but those that do come to 
clinical attention can develop various complications includ-
ing bone pain, deformity, pathological fractures, osteo-
arthritis, deafness and rarely osteosarcoma [2, 3]. Paget’s 
disease is a complex disorder. Current evidence suggests 
that genetic factors play a key role in susceptibility [4], but 
there is also a strong environmental component evidenced 
by the fact that the disease has become less common and 
less severe in several countries over recent decades [5–7]. 
Several potential environmental triggers for Paget’s dis-
ease of bone (PDB) have been suggested including dietary 
calcium intake [8], vitamin D deficiency [9] and excessive 
biomechanical loading of affected bones [10], but the most 
widely studied is paramyxovirus infection [11, 12]. Para-
myxoviruses were first implicated as a potential trigger of 
PDB by the morphological finding of nuclear inclusion 
bodies in osteoclast nuclei which were thought to resemble 
measles nucleocapsids [13, 14]. Despite extensive research 
over the past 30 years, the role of paramyxovirus infection 
in the pathogenesis of PDB remains controversial [15, 16]. 
Some researchers have reported finding evidence of mea-
sles virus (MV) nucleic acids or antigens in cells and tis-
sues from patients with the disease [17–20]. Respiratory 
Abstract Paget’s disease of bone (PDB) is a common 
skeletal disorder characterised by focal abnormalities of 
increased and disorganised bone turnover. Genetic factors 
play a central role in the pathogenesis of PDB but environ-
mental factors also contribute. Measles virus (MV), res-
piratory syncytial virus (RSV) and canine distemper virus 
(CDV) have all been implicated as potential disease trig-
gers but the data are conflicting. Since chronic paramyxo-
virus infection with measles is known to be accompanied 
by increased production of antiviral antibodies, we have 
analysed circulating concentrations of antibodies to MV, 
CDV, and RSV as well as mumps, rubella and varicella 
zoster virus (VZV) in 463 patients with PDB and 220 aged 
and gender-matched controls. We also studied the relation 
between viral antibody concentrations and various markers 
of disease severity and extent in 460 PDB patients. A high 
proportion of cases and controls tested positive for antiviral 
antibodies but there was no significant difference in circu-
lating antibody concentrations between PDB cases and con-
trols for MV, CDV, RSV, rubella or VZV. However, mumps 
virus antibody levels were significantly higher in the PDB 
cases (mean ± SD = 3.1 ± 0.84 vs. 2.62 ± 0.86. p < 0.001). 
There was no association between disease severity and cir-
culating antibody concentrations to any of the viruses. In 
conclusion, we found no evidence to suggest that PDB is 
associated with abnormalities of immune response to mea-
sles or other paramyxoviruses, although there was evidence 
of a greater antibody response to mumps. The results do 
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syncytial virus antigens were also detected in one study 
[21], and in another evidence was presented to suggest that 
antigens for both MV and respiratory syncytial virus (RSV) 
may be present [22]. Canine distemper virus (CDV) nucleic 
acids have also been reported by one group to be present in 
Pagetic bone cells [23, 24], whereas other researchers failed 
to find evidence of paramyxovirus nucleic acids or protein 
in bone tissue or peripheral blood from PDB patients [15, 
25–29]. A characteristic feature of the persistent measles 
infection, subacute sclerosing panencephalitis, is the pres-
ence of a marked increase in antiviral antibodies both in 
the serum and cerebrospinal fluid [30, 31]. Based on this 
observation, several researchers have measured antibodies 
to paramyxoviruses in patients with PDB [32–35]. These 
studies yielded negative results, but the sample sizes were 
small and had limited power to detect possible differences 
between PDB cases and controls. Here, we have evaluated 
the antibody response to paramyxoviruses in PDB in the 
largest study performed to date using a case control design 
and determined if antibody concentrations were associated 
with disease extent or complications. We also evaluated 
the antibody response to other common viral infections not 
previously implicated in the pathogenesis of PDB including 
mumps, rubella and varicella zoster virus.
Patients and Methods
Patients
The study cohort comprised 463 patients who partici-
pated in the Paget’s disease, Randomised Trial of Inten-
sive versus Symptomatic Management (PRISM) study 
(ISRCTN12989577) [36, 37]. Participants were included in 
this study if sufficient serum was available from the base-
line study visit for analysis of the antibodies of interest. 
One subject included in this study had a history of osteosar-
coma. The controls comprised 202 age and gender match 
subjects not known to have PDB who were predominantly 
spouses of PRISM participants.
Clinical Assessments
The clinical assessments performed within the PRISM 
study have been previously described [36]. Health-related 
quality of life was assessed by the SF-36 questionnaire. 
Deformity was assessed by the attending physicians who 
were asked to assess whether the patient had clinical evi-
dence of bone deformity using a three-point scale as fol-
low: 0 = no deformity; 1 = mild or moderate deform-
ity and 2 = severe deformity. The presence of bone pain 
was recorded and physicians were asked to assess if they 
thought the pain was caused by PDB. Information was 
collected on previous fractures and whether they had 
occurred in affected bone; on orthopaedic surgical proce-
dures; on the use of a hearing aid for deafness in those with 
skull disease; on age at first diagnosis of PDB; and fam-
ily history of PDB. The extent of PDB was recorded based 
on involvement on bone scan examination. Information was 
recorded on previous bisphosphonate treatment, and the 
number of treatment courses given. Based on the clinical 
data, we devised a composite scoring system for disease 
severity as previously described [38] taking into account 
the number of affected bones, age at first diagnosis, family 
history, presence of bone pain, pathological fracture, ortho-
paedic surgery for PDB, bone deformity, deafness associ-
ated with skull involvement and previous bisphosphonate 
treatment for PDB.
Genotyping
Genotyping was conducted for SQSTM1 mutations by DNA 
sequencing on DNA extracted from peripheral blood using 
standard techniques as previously described [38].
Detection of Antiviral Antibodies
Enzyme-linked immunosorbent assays (ELISA) were used 
for the detection and quantitative determination of IgG 
antibodies to MV, Rubella, Mumps, Varicella Zoster Virus 
(VZV), RSV and CDV. The ELISA were performed on 
serum samples that had been collected at the baseline visit 
of the PRISM study between 2001 and 2004 and stored fro-
zen at −80oc until analysis in the present study. We used 
the Trinity Biotech Captia assays TM for MV (catalogue 
number 2326000), mumps (catalogue number 2325900) 
rubella (catalogue number 2325300) and VZV (cata-
logue number 2325600). We used the MP Biomedical IgG 
ELISA (catalogue number 071-516002) for RSV. For CDV, 
we used the  ImmunoComb® antibody test kit. All assays 
were performed according to the manufacturer’s instruc-
tions. The results of the ELISA assays were read on a Syn-
ergy HT Multi-Mode Micro plate reader (Bio-Tek), 450 nm 
filter. Dual wavelength was used and the reference filter 
set to 600–650  nm. All samples were tested in duplicate 
and the mean value of the two samples calculated. Dupli-
cate samples that yielded values that differed by more than 
20% were repeated. With the exception of CDV, data were 
expressed as the immune status ratio (ISR). This was cal-
culated by dividing the optical density value of the patient 
sample by a calibrator value provided with the kit. These 
results were converted to International Units (IU) using 
the natural exponential function f(x) = ex. For CDV, semi-
quantitative analysis was performed based on a colour scale 
provided with the kit using Comb Scan software. The refer-
ence ranges are shown in Table 1.
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Statistical Analysis
Differences in viral antibody concentrations in PDB cases 
and controls were assessed quantitatively using Student’s 
t-test and semi-quantitatively by χ2 test in which patients 
were categorised into two groups if antibody concentra-
tions suggested there had been previous infection. The 
relation between viral antibody titres and disease extent 
was evaluated by dividing PDB subjects into three groups 
based on the severity score and comparing viral antibody 
titres and other clinical characteristics between the groups 
by ANOVA or χ2 test as appropriate. The significance 
level was set at 0.008 to account for the fact that antibodies 
against six different viruses were tested.
Results
Antiviral Antibodies in PDB Cases and Controls
Demographic characteristics and antiviral antibody concen-
trations in PDB cases and controls are shown in Table  2. 
A high proportion of PDB cases and controls tested posi-
tive for measles virus, rubella, VZV, mumps and RSV indi-
cating previous infection, with no significant difference 
between the groups. All cases and controls tested posi-
tive for at least one virus and more than 90% tested posi-
tive for four of the viruses. Antibodies were also detected 
that cross-reacted with distemper virus in about 45% of 
PDB cases and controls with no difference between the 
groups. Quantitative analysis showed that antibody con-
centrations did not differ between cases and controls for 
MV, CDV, RSV and VZV (Table  2). However, antibody 
concentrations for mumps virus were significantly higher 
in PDB cases as compared with controls (3.00 ± 0.85 vs. 
2.56 ± 0.89; p < 0.001). For rubella virus, antibody concen-
trations in PDB cases were also higher, but this was not sig-
nificant taking multiple testing into account (29.1 ± 11.4 vs. 
27.30 ± 9.82, p = 0.039).
Relation Between Severity of PDB and Antiviral 
Antibodies
To determine if circulating antibody concentrations were 
related to the severity of PDB, patients were grouped into 
three categories based on the disease severity score as 
previously described [38]. Mild disease was defined as a 
score of 3 or less, moderate disease as a score of 4 to 6 
and severe disease as a score of 7 or more. The result is 
shown in Table 3. There was no association between dis-
ease severity and circulating antibody concentrations 
to any of the viruses tested. We repeated the analysis for 
number of affected bones but no association was observed 
(data not shown). The presence of SQSTM1 mutations was 
associated with greater severity. Not surprisingly, patients 
with more severe disease had a significantly lower physical 
functioning as assessed by the SF36 instrument. Interest-
ingly, there was difference between the severity groups in 
SF36 bodily pain or mental functioning. The patient with 
a history of osteosarcoma tested positive for all the viruses 
studied, except CDV where the results were negative. The 
circulating antibody concentrations were unremarkable in 
this patient.
Antiviral Antibodies and SQSTM1 Mutations
It has previously been suggested that measles virus infec-
tion may interact with SQSTM1 mutations to act as a trig-
ger for PDB [39]. To determine whether antibody concen-
trations were associated with SQSTM1 mutation status, 
we performed a subgroup analysis in which we analysed 
circulating antibody concentrations in SQSTM1 mutation 
positive and negative PDB cases as compared with con-
trols. The results are summarised in Table 4. There was no 
difference in circulating antibody concentration to any of 
the viruses tested according to SQSTM1 mutation status, 
although concentration of mumps virus antibodies were 
higher in SQSTM1 negative and SQSTM1 positive PDB 
cases as compared with SQSTM1 negative controls.
Discussion
The aim of this study was to determine if antibody response 
to measles virus, RSV or distemper virus was associated 
with the occurrence or severity of PDB. In addition to test-
ing for antibodies to the paramyxoviruses which have pre-
viously been implicated in PDB [11, 12, 22], we also meas-
ured antibody concentrations to other common viruses such 
as mumps, rubella and varicella zoster virus.
The results showed that a high proportion of patients in 
both the PDB group and the control group had circulating 
antibodies to the viruses tested indicating that previous 
Table 1  Reference ranges for viral antibodies
Values are in international units with the exception of CDV which are 
arbitrary units. Negative results indicate that there is no serological 
evidence of previous infection; positive results indicate a previous 
infection; values in between are indeterminate
Virus Negative Indeterminate Positive
Measles ≤0.06 0.061–0.09 ≥0.091
Mumps ≤0.9 0.91–1.09 ≥1.10
Rubella ≤6.5 6.6–8.1 ≥8.2
Varicella zoster ≤0.11 0.12–0.14 ≥0.15
Respiratory syncytial virus ≤0.54 0.55–1.09 ≥1.10
Canine distemper 0 1–2 ≥3
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infection had occurred. For most viruses, the prevalence 
of those that tested positive was greater than 95% with no 
difference between cases and controls. These results con-
firm the findings of previous small scale studies which 
failed to find a difference in antiviral antibody concentra-
tions between PDB cases and controls [32–35]. For CDV, 
only about 45% of cases and controls tested positive. 
Since there is extensive homology within the paramyxo-
virus family [40–44], it is unclear if these antibodies 
truly represented previous distemper virus infection or 
were cross reacting antibodies due to exposure to other 
paramyxoviruses such as measles [45]. Further studies 
will be required to investigate this fully. On quantitative 
testing, there was no significant difference in circulat-
ing antibody concentrations between cases and controls 
except for mumps virus where concentrations were sig-
nificantly higher in cases. This raises the possibility that 
the immune response to mumps may be altered in PDB 
Table 2  Clinical characteristics 
and antibody concentrations in 
PDB cases and controls
The values shown are mean SD and number (%). The p-values refer to differences between cases and con-
trols assessed by Students t-test, Fishers exact test or χ2 test. For MV, RSV, Mumps, VZV and Rubella 
participants were coded as having positive serology when antibody concentrations were above the refer-
ence range suggested by the manufacturer as indicating previous infection. Information on antibody con-
centrations for CDV was missing for two PDB patients. For CDV, subjects who tested positive or high were 
considered to have positive serology
PDB (n = 463) Controls (n = 221) p-value
Age (years) 72.4 ± 8.0 72.2 ± 8.4 0.75
Male 240 (51.8%) 114 (51.5%) 0.95
Age at diagnosis 64.3 ± 10.5 –
Family history PDB 70 (15.1%) –
SQSTM1 mutation 38 (8.4%)
Number of affected sites –
 1 222 (47.1%)
 2 141 (30.4%)
 3 62 (13.4%)
 >4 38 (8.2%)
Fractures in pagetic bone 47 (10.1%)
Orthopaedic surgery 83 (17.9%)
Previous bisphosphonate 353 (76.2%) –
Deafness and skull involvement 34 (7.3%)
Bone deformity 172 (37.1%)
Bone pain 345 (74.5%)
Adjusted alkaline phosphatase 1.18 ± 1.01 –
Measles virus
 Antibody concentration (IU/ml) 3.00 ± 12.3 2.32 ± 6.16 0.36
 Previous infection 459 (99.1%) 217 (98.2%) 0.28
Respiratory syncytial virus
 Antibody concentration (IU/ml) 227 ± 144 220 ± 143 0.57
 Positive serology 425 (91.8%) 204 (92.3%) 0.881
Canine distemper virus
 Antibody concentration (IU/ml) 2.37 ± 1.08 2.39 ± 1.16 0.79
 Positive serology 208 (45.1%) 100 (45.2%) 1.00
Mumps virus
 Antibody concentration (IU/ml) 3.00 ± 0.85 2.56 ± 0.89 0.0001
 Positive serology 451 (97.4%) 210 (95.0%) 0.11
Varicella zoster virus
 Antibody concentration (IU/ml) 0.872 ± 0.728 0.784 ± 0.741 0.147
 Positive serology 448 (96.8%) 215 (97.3%) 0.81
Rubella virus
 Antibody concentration (IU/ml) 29.1 ± 11.4 27.30 ± 9.82 0.039
 Positive serology 451 (97.4%) 215 (97.3%) 1.00
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and suggests that the role of mumps in PDB might be 
worth further study.
We also sought to determine if the levels of virus anti-
body were associated with the severity of PDB. For this 
analysis, patients were divided into three categories of 
mild moderate and severe PDB based on disease extent 
and complications as previously described [38]. No sig-
nificant association between circulating antibody levels and 
disease severity or extent was observed. Given that per-
sistent virus infections such as SSPE are associated with 
high titres of antibody production [30, 31], this observation 
argues strongly against the possibility that there is a state of 
Table 3  Antiviral antibodies and other variables in relation to severity of PDB
Patients with mild PDB had a disease severity score of 3 or less, those with moderate a score of 4–6 and those with severe PDB a score of 7 or 
more. Values are mean ± standard deviation or numbers (%). The p-values refer to differences across groups, as assessed by ANOVA
Mild PDB (n = 152) Moderate PDB (n = 163) Severe PDB (n = 145) p-value
Age (years) 74.7 ± 6.2 71.2 ± 8.6 71.5 ± 8.6 <0.0001
Male gender 85 (55.9%) 78 (47.8%) 76 (52.4%) 0.35
Measles virus (IU/ml) 4.5 ± 18.6 1.9 ± 6.0 2.4 ± 8.9 0.13
Respiratory syncytial virus (IU/ml) 224.5 ± 147.9 228.8 ± 144.7 227.5 ± 141.6 0.96
Canine distemper virus (IU/ml) 2.40 ± 1.11 2.42 ± 1.11 2.24 ± 1.01 0.30
Mumps virus (UI/ml) 2.96 ± 0.91 3.05 ± 0.82 3.0 ± 0.81 0.60
Varicella zoster virus (IU/ml) 0.86 ± 0.76 0.88 ± 0.66 0.88 ± 0.77 0.95
Rubella virus (IU/ml) 28.6 ± 11.6 30.0 ± 12.0 28.9 ± 10.7 0.38
SQSTM1 mutation 3 (2.0%) 16 (9.8%) 20 (13.8%) 0.001
SF36 bodily pain 40.2 ± 10.9 38.6 ± 10.7 38.0 ± 10.5 0.19
SF36 physical functioning 38.1 ± 11.0 36.2 ± 11.5 34.3 ± 10.4 0.02
SF36 mental functioning 47.9 ± 11.0 49.6 ± 11.3 47.7 ± 11.8 0.31
Table 4  Antiviral antibodies 
in PDB cases and controls 
according to SQSTM1 status
Values are mean ± SD or number (%). The p-values are from ANOVA for antibody concentrations and from 
χ2 test for the proportion of patients with previous infection. Information on antibody concentrations for 
CDV was missing for two PDB patients; one in the SQSTM1 positive and one in the SQSTM1 negative 
group
PDB SQSTM1 
+ve (n = 38)
PDB SQSTM1 −
ve (n = 425)
Control SQSTM1 
−ve (n = 221)
p-value
Age (years) 71.1 ± 6.1 72.6 ± 8.0 72.2 ± 8.6 0.56
Male gender 17 (44.7%) 223 (52.5%) 114 (51.6%) 0.65
Measles virus
 Antibody concentration (IU/ml) 2.65 ± 8.8 2.98 ± 12.5 2.31 ± 6.2 0.75
 Previous infection 38 (100%) 421 (99.1%) 217 (98.2%) 0.49
Respiratory syncytial virus
 Antibody concentration (IU/ml) 236.5 ± 138.9 225.9 ± 144.7 220.3 ± 143.4 0.78
 Previous infection 35 (92.1%) 390 (91.8%) 204 (92.3%) 0.97
Canine distemper virus
 Antibody concentration (IU/ml) 2.31 ± 1.35 2.37 ± 1.05 2.39 ± 1.16 0.91
 Previous infection 14 (37.8%) 194 (45.7%) 100 (45.2%) 0.64
Mumps virus
 Antibody concentration (IU/ml) 3.00 ± 0.92 3.00 ± 0.84 2.56 ± 0.89 0.0001
 Previous infection 37 (97.4%) 414 (97.4%) 210 (95.0%) 0.29
Varicella zoster virus
 Antibody concentration (IU/ml) 0.86 ± 0.72 0.87 ± 0.73 0.78 ± 0.74 0.34
 Previous infection 36 (94.7%) 412 (96.9%) 215 (97.3%) 0.73
Rubella virus
 Antibody concentration (IU/ml) 30.8 ± 11.9 28.9 ± 11.4 27.3 ± 9.8 0.09
 Previous infection 38 (100%) 413 (97.2%) 217 (97.3%) 0.35
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persistent paramyxovirus viral infection in PDB contrary to 
what has been suggested [46]. While the present study pro-
vides no support for the hypothesis that patients with PDB 
have persistent paramyxovirus infection, the study design 
cannot completely rule out the possibility that previous 
exposure to a viral illness early in life might play a role in 
PDB. However, as previously reported, there was a signifi-
cant association between disease severity and the presence 
of SQSTM1 mutations [38, 47] emphasising the importance 
of genetic factors in the pathogenesis of PDB and its sever-
ity. In summary, the present study does not provide support 
for the notion that persistent paramyxovirus infection is 
involved in the pathogenesis of PDB.
Acknowledgements This work was supported by grants from 
Arthritis Research UK (17646 and 13724) and the Paget’s Association 
(UK).
Author Contributions MR-V performed the experimental work, 
contributed to the design of the study, analysed the data and wrote the 
first draft of the paper. RU-M contributed to analysis and interpreta-
tion of the data and revised the manuscript. SHR obtained funding 
to support the study, contributed to design of the study, contributed 
to analysis and interpretation of the data and revised the manuscript.
Compliance with Ethical Standards 
Conflict of interest SHR reports having received consulting fees on 
behalf of his institution from Novartis and Merck and research grants 
to his institution from Amgen, Eli Lilly, and UCB. The other authors 
have no interests to declare.
Human and Animal Rights and Informed Consent The trial was 
approved by the UK Multicentre Research Ethics Committee for Scot-
land (MREC01/0/53); by local ethical review boards in the participat-
ing study centres and by the Medicines & Healthcare Products Regula-
tory Authority (CTA 21583/0002/001-0001). The study was included 
in the controlled clinical trials register (www.controlled-trials.com) 
and assigned the reference number ISRCTN12989577. All participants 
gave written informed consent to be included in the study.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Ralston SH (2013) Clinical practice. Paget’s disease of bone. N 
Engl J Med 368:644–650
 2. Tan A, Ralston SH (2014) Clinical presentation of Paget’s dis-
ease: evaluation of a contemporary cohort and systematic review. 
Calcif Tissue Int 95:385–392
 3. Sharma H, Jane MJ, Reid R (2005) Scapulo-humeral Paget’s sar-
coma: Scottish bone tumour registry experience. Eur J Cancer 
Care 14:367–372
 4. Vallet M, Ralston SH (2016) Biology and treatment of Paget’s 
disease of bone. J Cell Biochem 117:289–299
 5. Cundy HR, Gamble G, Wattie D, Rutland M, Cundy T (2004) 
Paget’s disease of bone in New Zealand: continued decline in 
disease severity. Calcif Tissue Int 75:358–364
 6. Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-
Montes J, Ralston SH (2013) Epidemiology of Paget’s dis-
ease of bone: a systematic review and meta-analysis of secular 
changes. Bone 55:347–352
 7. Poor G, Donath J, Fornet B, Cooper C (2006) Epidemiology of 
Paget’s disease in Europe: the prevalence is decreasing. J Bone 
Miner Res 21:1545–1549
 8. Siris ES (1994) Epidemiological aspects of Paget’s disease: 
family history and relationship to other medical conditions. 
Semin Arth Rheum 23:222–225
 9. Barker DJ, Gardner MJ (1974) Distribution of Paget’s diease 
in England, Wales and Scotland and a possible relationship 
with vitamin D deficiency in childhood. Br J Prev Soc Med 
28:226–232
 10. Solomon LR (1979) Billiard-player’s fingers: an unusual case 
of Paget’s disease of bone. Br Med J 1:931
 11. Friedrichs WE, Reddy SV, Singer FR, Roodman GD (2002) 
The pro and con of measles virus in Paget’s disease: pro. J 
Bone Miner Res 17:2293–2293
 12. Mee AP (1999) Paramyxoviruses and Paget’s disease: the 
affirmative view. Bone 24:19S–21S
 13. Rebel A, Malkani K, Basle M, Bregeon C (1974) Particularites 
ultrastructurales des osteoclasts de la maladie de Paget. Rev 
Rhum Mal Osteoartic 41:767–771
 14. Mills BG, Singer FR (1976) Nuclear inclusions in Paget’s dis-
ease of bone. Science 194:201–202
 15. Ralston SH, Afzal MA, Helfrich MH, Fraser WD, Gallagher 
JA, Mee A, Rima B (2007) Multicenter blinded analysis of 
RT-PCR detection methods for paramyxoviruses in relation to 
Paget’s disease of bone. J Bone Miner Res 22:569–577
 16. Rima BK, Gassen U, Helfrich MH, Ralston SH (2002) The pro 
and con of measles virus in Paget’s disease: con. J Bone Miner 
Res 17:2290–2292
 17. Reddy SV, Singer FR, Mallette L, Roodman GD (1996) Detec-
tion of measles virus nucleocapsid transcripts in circulating 
blood cells from patients with Paget disease. J Bone Miner Res 
11:1602–1607
 18. Reddy SV, Singer FR, Roodman GD (1995) Bone marrow 
mononuclear cells from patients with Paget’s disease con-
tain measles virus nucleocapsid messenger ribonucleic acid 
that has mutations in a specific region of the sequence. J Clin 
Endocrinol Metab 80:2108–2111
 19. Basle MF, Fournier JG, Rozenblatt S, Rebel A, Bouteille M 
(1986) Measles virus RNA detected in Paget’s disease bone 
tissue by in situ hybridization. J Gen. Virol 67(Pt 5):907–913
 20. Basle MF, Russell WC, Goswami KK, Rebel A, Giraudon P, 
Wild F, Filmon R (1985) Paramyxovirus antigens in osteo-
clasts from Paget’s bone tissue detected by monoclonal anti-
bodies. J Gen Virol 66(Pt 10):2103–2110
 21. Mills BG, Singer FR, Weiner LP, Holst PA (1981) Immu-
nohistological demonstration of respiratory syncytial virus 
antigens in Paget’s disease of bone. Proc Natl Acad Sci USA 
78:1209–1212
 22. Mills BG, Singer FR, Weiner LP, Suffin SC, Stabile E, Holst P 
(1984) Evidence for both respiratory syncytial virus and mea-
sles virus antigens in the osteoclasts of patients with Paget’s 
disease of bone. Clin Orthop Relat Res 183:303–311
 23. Gordon MT, Mee AP, Anderson DC, Sharpe PT (1992) Canine 
distemper transcripts sequenced from pagetic bone. Bone 
Miner 19:159–174
Antibody Response to Paramyxoviruses in Paget’s Disease of Bone 
1 3
 24. Gordon MT, Anderson DC, Sharpe PT (1991) Canine distem-
per virus localised in bone cells of patients with Paget’s disease. 
Bone 12:195–201
 25. Ralston SH, DiGiovine FS, Gallacher SJ, Boyle IT, Duff GW 
(1991) Failure to detect paramyxovirus sequences in Paget’s dis-
ease of bone using the polymerase chain reaction. J Bone Miner 
Res 6:1243–1248
 26. Helfrich MH, Hobson RP, Grabowski PS, Zurbriggen A, Cosby 
SL, Dickson GR, Fraser WD, Ooi CG, Selby PL, Crisp AJ, 
Wallace RG, Kahn S, Ralston SH (2000) A negative search for 
a paramyxoviral etiology of Paget’s disease of bone: molecu-
lar, immunological, and ultrastructural studies in UK patients. J 
Bone Miner Res 15:2315–2329
 27. Birch MA, Taylor W, Fraser WD, Ralston SH, Hart CA, Gal-
lagher JA (1994) Absence of paramyxovirus RNA in cultures 
of pagetic bone cells and in pagetic bone. J Bone Miner Res 
9:11–16
 28. Ooi CG, Walsh CA, Gallagher JA, Fraser WD (2000) Absence 
of measles virus and canine distemper virus transcripts in long-
term bone marrow cultures from patients with Paget’s disease of 
bone. Bone 27:417–421
 29. Matthews BG, Afzal MA, Minor PD, Bava U, Callon KE, Pitto 
RP, Cundy T, Cornish J, Reid IR, Naot D (2008) Failure to detect 
measles virus RNA in bone cells from patients with Paget’s dis-
ease. J Clin Endocrinol Metab 93:1398–1401
 30. Garg RK (2002) Subacute sclerosing panencephalitis. Postgrad 
Med J 78:63–70
 31. Kiessling WR, Hall WW, Yung LL, Ter M V (1977) Measles-
virus-specific immunoglobulin-M response in subacute scleros-
ing panencephalitis. Lancet 1:324–327
 32. Hamill RJ, Baughn RE, Mallette LE, Musher DM, Wilson DB 
(1986) Serological evidence against role for canine distemper 
virus in pathogenesis of Paget’s disease of bone. Lancet 2:1399
 33. Gordon MT, Bell SC, Mee AP, Mercer S, Carter SD, Sharpe PT 
(1993) Prevalence of canine distemper antibodies in the pagetic 
population. J Med Virol 40:313–317
 34. Basle M, Kouyoumdjian S, Pouplard A, Rebel A, Filmon R 
(1983) [Paget’s bone disease. preliminary serological study]. 
Pathol Biol 31:41–44
 35. Morgan-Capner P, Robinson P, Clewley G, Darby A, Pettingale 
K (1981) Measles antibody in Paget’s disease. Lancet 1:733
 36. Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby 
PL, Ralston SH (2010) Randomised trial of intensive bisphos-
phonate treatment versus symptomatic management in paget’s 
disease of bone. J Bone Miner Res 25:20–31
 37. Tan A, Goodman K, Walker A, Hudson J, MacLennan GS, Selby 
PL, Fraser WD, Ralston SH, for the PRISM-EZ investigators 
(2017) Long-term randomized trial of intensive versus sympto-
matic management in Paget’s disease of bone: the PRISM-EZ 
study. J Bone Miner Res. doi:10.1002/jbmr.3066
 38. Visconti MR, Langston AL, Alonso N, Goodman K, Selby PL, 
Fraser WD, Ralston SH (2010) Mutations of SQSTM1 are asso-
ciated with severity and clinical outcome in Paget’s disease of 
bone. J Bone Miner Res 25:2368–2373
 39. Kurihara N, Hiruma Y, Yamana K, Michou L, Rousseau C, 
Morissette J, Galson DL, Teramachi J, Zhou H, Dempster DW, 
Windle JJ, Brown JP, Roodman GD (2011) Contributions of the 
measles virus nucleocapsid gene and the SQSTM1/p62(P392L) 
mutation to Paget’s disease. Cell Metab 13:23–34
 40. Kallajoki M, Hyypia T, Halonen P, Orvell C, Rima BK, Kalimo 
H (1991) Inclusion body myositis and paramyxoviruses. Hum 
Pathol 22:29–32
 41. Sheshberadaran H, Norrby E, McCullough KC, Carpenter WC, 
Orvell C (1986) The antigenic relationship between measles, 
canine distemper and rinderpest viruses studied with monoclonal 
antibodies. J Gen Virol 67(Pt 7):1381–1392
 42. Orvell C, Norrby E (1980) Immunological relationships between 
homologous structural polypeptides of measles and canine dis-
temper virus. J Gen Virol 50:231–245
 43. Rosenblatt S, Eizenberg O, Ben-Levy R, Lavie V, Bellini WJ 
(1985) Sequence homology within the morbilliviruses. J Virol 
53:684–690
 44. Sanchez A, Banerjee AK, Furiuchi Y, Richardson MA (1986) 
Conserved structures among the nucleocapsid proteins of the 
paramyxoviridae: complete nucleotide sequence of human 
parainfluenza virus type 3 NP mRNA. Virology 152:171–180
 45. Stephenson JR, ter Meulen V (1979) Antigenic relationships 
between measles and canine distemper viruses: comparison of 
immune response in animals and humans to individual virus-
specific polypeptides. Proc Natl Acad Sci USA 76:6601–6605
 46. Roodman GD, Windle JJ (2005) Paget disease of bone. J Clin 
Invest 115:200–208
 47. Albagha OM, Visconti MR, Alonso N, Wani S, Goodman K, 
Fraser WD, Gennari L, Merlotti D, Gianfrancesco F, Esposito 
T, Rendina D, Di SM, Isaia G, Brandi ML, Guisti F, Del Pino-
Montes J, Corral-Gudino L, Gonzalez-Sarmiento R, Ward L, Rea 
SL, Ratajczak T, Walsh JP, Ralston SH (2013) Common suscep-
tibility alleles and SQSTM1 mutations predict disease extent and 
severity in a multinational study of patients with Paget’s disease. 
J Bone Miner Res 28:2238–2246
